BPMC News and Press, Blueprint Medicines Corporation From 01/17/24

2024-01-17 07:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-09 11:40:35 ET More on Madrigal, Viking, etc. Madrigal Pharmaceuticals: A Deeper Look At A Looming NASH Play Viking: Results From 2 Clinical Trials Of Weight Loss Drug Ahead, Other Catalysts On Tap Madrigal Pharmaceuticals: Preparing For Resmetirom's Commerci...

2024-01-09 09:45:02 ET Wells Fargo analyst issues BUY recommendation for BPMC on January 9, 2024 10:00AM ET. The previous analyst recommendation was Buy. BPMC was trading at $83.615 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...

Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire -- AYVAKIT ® (avapritinib) launch in indolent systemic mastocytosis to drive strong revenue growth in 2024, with ongoing U.S. la...

2024-01-04 16:28:54 ET Summary Today, we take a look at Blueprint Medicines Corporation, whose shares have nearly doubled in the past two months due to strong sales of its precision medicine Ayvakit. Ayvakit's label expansion into indolent systemic mastocytosis suggests blockbuste...

2024-01-04 14:57:40 ET More on SPDR S&P Biotech ETF: Biopharmaceutical Stocks: The Rally Has Just Begun Get Ready For The New Biotech Bull Market Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biotechs p...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

2023-12-22 12:00:02 ET Raymond James analyst issues STRONG BUY recommendation for BPMC on December 22, 2023 12:00PM ET. The previous analyst recommendation was Strong Buy. BPMC was trading at $88.13 at issue of the analyst recommendation. The overall analyst consensus : ...

2023-12-21 13:05:16 ET Summary Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions. ...

Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Dec. 18, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland , Chief Executive Officer, will pres...